The ASCO Post

The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members.

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Breast Cancer Patients May Skip Nodal Irradiation After Neoadjuvant Chemotherapy, Study Suggests

    Broke On: Thursday, 07 December 2023 Breast cancer patients who have lymph node-negative disease after neoadjuvant chemotherapy may be able to safely forgo adjuvant regional nodal irradiation (RNI). The 5-year disease-free survival rate was similar among patients who received RNI and those who did not. The lead researcher, Eleftherios Mamounas, disclosed ties to the biopharmaceutical industry.

  • American Cancer Society Expands Lung Cancer Screening Guidelines; Other Health Updates

    Broke On: Thursday, 02 November 2023 The American Cancer Society has updated its lung cancer screening guidelines to include nearly 5 million more adults who smoke or used to smoke. The new guidelines recommend annual lung cancer screenings for individuals aged 50 to 80 years old who have a 20-year or greater pack-year history. The update is expected to increase the number of eligible patients by about 37%. Insurance coverage for lung cancer screenings based on this updated guideline may vary. Recent medical studies and trials have highlighted the effectiveness of Selpercatinib vs Chemotherapy in treating RET Fusion–Positive NSCLC and the use of Bispecific T-Cell Engager Tarlatamab in treating Small Cell Lung Cancer. A novel blood test for early cancer detection is showing potential. Crowdfunding campaigns are playing a significant role in covering medical expenses for cancer survivors. A drop in E-Cigarette use among High School Students has been observed. The impact of air pollution on breast cancer risk is being studied.